CD34 and acute lymphoblastic leukemia: A study by the Nordic Society of Pediatric Hematology and Oncology (NOPHO) in Denmark analyzed 200 B-ALL patients, identifying the CD34+/CD38dim/+TdTdim/+ immunophenotype as a predictor of poor induction response and MRD positivity post-induction.